Compare CVS Health Corp (CVS) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Visa Inc — how do they compare? CVS Health Corp trades at $107.57 (market cap $135.48B), while Visa Inc trades at $358.77 (market cap $677.06B). The key difference: Visa Inc is far larger — about 5× CVS Health Corp's market cap, and CVS Health Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| CVS | V | |
|---|---|---|
Market Cap | $135.48B | $677.06B |
Sector | Health | Financials |
52-Week High | $106.18 | $362.13 |
52-Week Low | $58.75 | $295.52 |
Enterprise Value | $202.02B | $687.65B |
Dividend Yield | 2.51% | 0.75% |
Volume | — | 10,431,336 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
Visa (V) trades at $357.01, down 0.21% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.31 exceeding the $3.10 estimate. Revenue grew to $40 billion in 2025, and net income margin remains robust at 51.68%. Recent news highlights Visa's expansion into AI-driven commerce and stablecoin partnerships, positioning it for future growth in digital payments.
Outlook remains positive with an 85% analyst buy rating and a consensus price target of $394.50, implying 10.5% upside. Key risks include competitive threats from fintech and regulatory pressures. The stock's valuation multiples are elevated, but consistent profitability and strategic initiatives support long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
